Discovery of First-in-Class Carbonic Anhydrase/Histone Deacetylase Dual Inhibitors with Antiproliferative Activity in Cancer Cells

This study reports <i>in vitro</i> evidence supporting a new class of compounds capable of independently targeting the tumor-associated human (h) carbonic anhydrase (CA; EC 4.2.1.1) and histone deacetylase (HDAC; EC 3.5.1.98) isoforms as first-in-class agents endowed with enhanced antiproliferative effects and safety profiles when compared to their constitutive counterparts as well as to clinically used drugs. The binding modes of both the CA- and HDAC-directed moieties were investigated through X-ray and molecular modeling experiments, respectively, thus delivering detailed Structure-Activity Relationship (SAR) knowledge.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-10-28
DOI
https://doi.org/10.1021/acs.jmedchem.5c01788
Citations
2
Primary Topic
Enzyme function and inhibition
Type
article
Field-Weighted Citation Impact
1.61
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of First-in-Class Carbonic Anhydrase/Histone Deacetylase Dual Inhibitors with Antiproliferative Activity in Cancer Cells

Rino Ragno, Daniela Trisciuoglio, Antonello Mai, Silvia Peppicelli et al.
2 citations
Journal of Medicinal Chemistry
Enzyme function and inhibition
1.61
article

Discovery of First-in-Class Carbonic Anhydrase/Histone Deacetylase Dual Inhibitors with Antiproliferative Activity in Cancer Cells

Rino Ragno, Daniela Trisciuoglio, Antonello Mai, Silvia Peppicelli, Lido Calorini, Clemens Zwergel, Murat Bozdağ, Elena Andreucci, Alessio Biagioni, Fabrizio Carta, Sérgio Valente, Andrea Angeli, Roberta Astolfi, Alessia Raucci, Lidia Giuliani, Nabil Mroweh
article en
2 citations

Abstract

This study reports <i>in vitro</i> evidence supporting a new class of compounds capable of independently targeting the tumor-associated human (h) carbonic anhydrase (CA; EC 4.2.1.1) and histone deacetylase (HDAC; EC 3.5.1.98) isoforms as first-in-class agents endowed with enhanced antiproliferative effects and safety profiles when compared to their constitutive counterparts as well as to clinically used drugs. The binding modes of both the CA- and HDAC-directed moieties were investigated through X-ray and molecular modeling experiments, respectively, thus delivering detailed Structure-Activity Relationship (SAR) knowledge.

Journal of Medicinal ChemistryVol. 68(21)
Institute of Molecular Biology and Pathology (IT), Istituto Nazionale di Fisica Nucleare, Sezione di Firenze (IT), Istituto Pasteur (IT), National Research Council (IT), University of Florence (IT), Sapienza University of Rome (IT)
Openalex Percentile: Top 14%
Enzyme function and inhibition
1.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.